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Abstract: One major limitation for the vascularization of bone substitutes used for filling is the
presence of mineral blocks. The newly-formed blood vessels are stopped or have to circumvent
the mineral blocks, resulting in inefficient delivery of oxygen and nutrients to the implant. This
leads to necrosis within the implant and to poor engraftment of the bone substitute. The aim of
the present study is to provide a bone substitute currently used in the clinic with suitably guided
vascularization properties. This therapeutic hybrid bone filling, containing a mineral and a polymeric
component, is fortified with pro-angiogenic smart nano-therapeutics that allow the release of angio-
genic molecules. Our data showed that the improved vasculature within the implant promoted new
bone formation and that the newly-formed bone swapped the mineral blocks of the bone substitutes
much more efficiently than in non-functionalized bone substitutes. Therefore, we demonstrated that
our therapeutic bone substitute is an advanced therapeutical medicinal product, with great potential
to recuperate and guide vascularization that is stopped by mineral blocks, and can improve the
regeneration of critical-sized bone defects. We have also elucidated the mechanism to understand
how the newly-formed vessels can no longer encounter mineral blocks and pursue their course
of vasculature, giving our advanced therapeutical bone filling great potential to be used in many
applications, by combining filling and nano-regenerative medicine that currently fall short because
of problems related to the lack of oxygen and nutrients.
Keywords: therapeutic bone filling; pro-angiogenic smart nanotechnology; hybrid bone substitute;
smart nano-active complexes
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1. Introduction
Traumas, tumors, and infections could all induce bone defects. Small, non-critical sized
bone defects do not pose a significant challenge, and could be treated with conventional
approaches [1]. Critical-sized bone defects, however, are generally considered impossible
to treat by conventional medical treatments, and require either bone substitutes or bone
grafts [2–6]. Although the size varies depending on the anatomic location of the defect
and the state of the surrounding tissue, bone defects larger than 2.5 cm are considered
critical-sized bone defects in humans [7,8].
Recently, biphasic biomimetic bone substitutes were developed to replace autologous
bone transplants, which are currently the gold standard in orthopedic surgery and trauma-
tology [9–11]. Mimicking the natural composition of the bone tissue, these biomaterials
contain an organic phase (e.g., collagen) associated to a mineral phase (e.g., hydroxyapatite).
The former offers suitable conditions for the cells to graft, proliferate, and differentiate,
the latter fills the bone defects, replacing the bone in terms of resistance to mechanical
stimuli [9–13]. This new generation of bone substitutes aims at overcoming important
limitations of the autograft technique, as the necessity of a double surgery and, therefore,
occupies a relevant place in the field of orthopedic surgery.
Regardless of the approach used, the treatment of large bone defects remains a chal-
lenge for medical practitioners. Large engineered cellular constructs fail to integrate into
the host tissues, because the lack of nutrients and oxygen leads to cell necrosis or ischemia,
especially at the core of the graft. This largely depends on the slow speed by which the
host vasculature colonizes the implant, which implies that several weeks are needed for
the functional vascularization of implants larger than a few millimeters [14–20].
It has been reported that, for long-bone defects larger than 6 cm, vascularized bone
substitutes induce a faster healing than conventional ones; therefore, the ideal bone substi-
tute should actively promote its own vascularization from the host tissues [18,19,21]. For
bone tissue engineering, several types of bioactive materials were developed, which couple
improved capabilities for tissue repair with the presence of angiogenic factors, like Vascular
endothelial growth factor (VEGF) [22,23], platelet-derived growth factor (PDGF) [24,25],
bone morphogenetic protein (BMP) [26], or fibroblast growth factor (FGF) [27,28]. Among
these, VEGF was shown to play a key part in bone repair and to increase bone healing
in vivo [29–31]. The 165-amino acid form of VEGF (VEGF165) has angiogenic activity and
can bind heparin (HEP) through its heparin-binding domain [32–35]. However, both the
kinetic of release of VEGF and its local concentration are crucial for the vascularization of
biomaterials. A swift local release of highly concentrated VEGF promotes increased vascu-
lar permeability, leading to the formation of non-functional blood vessels [36]. Opposed to
that, a sustained release of low doses of pro-angiogenic molecules is essential to support
the correct vascularization of implanted biomaterials and boost their efficiency in tissue
repair [37–42].
The advent of third generation biomaterials expanded the array of possibilities to
achieve a functional engraftment of the implant, with the addition of living cells [43].
Human umbilical vein endothelial cells (HUVECs), for example, have been largely used for
their capacity to generate vascular networks in vitro; however, owing to their limited acces-
sibility, they are hardly transferable to the clinic [10,17]. Recently, adult mesenchymal stem
cells (MSCs) were shown to improve tissue healing, thanks to their angiogenic, antiapop-
totic and immunomodulatory effects [44–48]. Moreover, it was shown that mesenchymal
stem cells also play a role in the maintenance of a long-lasting vasculature in engineered
constructs, as they can differentiate into both endothelial and perivascular cells [21,49–51].
The main objective of this work was not to regenerate bone, we only focused on
critical bone lesions, which could not be regenerated through regenerative medicine or
filled with the usual bone substitutes due to the lack of vascularization. Therefore, we
developed a strategy to induce the functional vascularization of large bone substitutes,
in vivo, using angiogenic factors and materials already used as bone substitutes. We used
(1) a biphasic bone substitute currently used in the clinic; (2) our patent-pending smart
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nano-active complex (SNC) technology, providing the release of growth factors; (3) a
complex of VEGF165 and HEP, to induce vasculoneogenesis; and (4) multipotent human
MSCs. Here we report how the vasculoneogenesis induced within the transplanted bone
substitute by the pro-angiogenic SNCs promote a faster and more functional regeneration
of the bone, improving the therapeutic potential of our bioengineered bone substitute in
treating critical-sized bone defects.
2. Materials and Methods
2.1. Deposition of the HEP/VEGF165 Complexes
Drops of HEP (500 µg mL−1), VEGF165 (200 µg mL−1), or HEP/VEGF165
(500 µg mL−1/200 µg mL−1) in 20 mM/0.15 mM Tris/NaCl, pH 6.8 solution (Sigma-
Aldrich, Saint-Quentin-Fallavier, France) were laid on cover glass and dried. Salt crystals
from buffer were solubilized in deionized water, by 2 rinsing steps of 5 min each. This
deposition procedure was repeated 6 times to increase the quantity of material.
2.2. Scanning Electron Microscopy (SEM) and Atomic Force Microscopy (AFM) Study
In order to analyze the formation of HEP/VEGF-SNCs on the bone substitutes, sam-
ples were fixed with 4% paraformaldehyde (PFA) for 10 min at 4 ◦C. After dehydration, the
specimens were observed by mean of SEM (either with Hitachi TM1000 or FEG Sirion XL;
FEI) in conventional high vacuum mode with a secondary electron detector. A commercial
stand-alone AFM microscope Solver Pro (Nt-Mdt Inc., Moscow, Russia) was used to acquire
AFM images. Tapping imaging mode was used, with NSG 10 cantilever with a typical
resonance frequency of 105 kHz, and a spring constant of 2 N m−1. The image resolution
was set to 512 × 512, with a scanning rate of 1 Hz. Images were analyzed using the open
source software Gwyddion 2.24 [52].
2.3. Smart Nano-Active Complexes Deposition on Bone Substitute
Antartik® sponges (10% collagen I and III, 90% ceramic; Medical Biomat,
Vaulx-en-Velin, France) were cut in 5 mm wide fragments and placed in a 96-well plate.
They were sterilized with UV light (254 nm, 30 W, distance 20 cm, 30 min exposure).
Chitosan/HEP/VEGF-SNCs were applied via layer-by-layer deposition, as previously de-
scribed [38]. Briefly, bone substitutes were alternately dipped in 500-µg mL−1 chitosan solu-
tion (Protasan UP CL 113, NovaMatrix, Sandvika, Norway) and 500-µg mL−1/200 ng mL−1
HEP/VEGF complex solution in 20 mM/0.15 mM Tris/NaCl, pH 6.8. After each bath,
bone substitutes were rinsed three times for 5 min in Tris/NaCl buffer. Before use, bone
substitutes were equilibrated in serum-free Dulbecco’s Modified Eagle Medium (D-MEM).
2.4. Molecular Modeling of the HEP-VEGF165 Interactions
To prepare the starting structure for simulation, the HEP Sodium salt (CAS 9041-08-1)
and VEGF165 heparin binding domain coordinates (PDB id: 2VGH, 55 amino acids) were
extracted from the PDB structure files [53]. Partial atomic charges for heparin sodium salt
molecule were assigned based on the AM1-BCC method using the antechamber function of
AmberTools [54,55]. The van der Waals and bonded parameters for HEP were taken from
the general amber force field (GAFF) [56]; the AMBER format files of these molecules were
then converted to the GROMACS format using the ACPYPE python script. Using ClusPro
and PatchDock docking programs, complexes of heparin and VEGF were generated [57–59].
The coordinates of the 6 best complexes were the selected to generate the topology file for
each complex to run molecular dynamics (MD) simulations.
MD simulations were performed using GROMACS-4.6 for a period of 30 ns using
explicit water model. The complex was placed in the center of a cubic periodic box and
solvated by the addition of SPC water molecules. The net charge on the system was then
neutralized by adding counter ions as required. The energy minimization was done using
the steepest descent algorithm. The temperature and pressure were maintained at 300 K
and 1 atm using the v-rescale temperature and Parrinello–Rahman pressure coupling
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method [60,61]. Production simulations were performed for 30 ns with a 2 fs time step.
In order to calculate the interaction free energies of the heparin and VEGF complexes,
we used the MM/PBSA protocol. The calculations were performed using the g_mmpbsa
tool82, which implements the MM-PBSA approach using the GROMACS software pack-
ages [62]. The MM/PBSA energies were obtained from samples of 100 snapshots (for each
complex) that were extracted from the MD trajectories. All calculations were done using
computational time on BWUniCluster Karlsruhe.
2.5. Cell Culture
Green fluorescent protein-expressing HUVECs (PELOBiotech, Martinsried, Germany)
and hMSCs from the bone marrow (PromoCell, Heidelberg, Germany) were cultured
in the respective complete media (endothelial growth medium; mesenchymal stem cells
growth medium, PromoCell) at 37 ◦C in a humidified atmosphere with 5% CO2. Moreover,
1.5 × 104 hMSCs were seeded on each Antartik® sponge fragment deposited or not with
HEP/VEGF-SNCs, and cultured for 7 days in mesenchymal stem cell growth medium.
After 7 days, 5.5 × 104 GFP-HUVECs were seeded on the same samples and cultured
in a medium consisting of half hMSCs growth medium, and half endothelial growth
medium [63]. Bone substitute fragments seeded with cells were cultured for a total of
21 days, and then processed according to downstream applications.
2.6. Cell Biocompatibility Analysis
alamarBlue® (Thermo Fisher Scientific, Waltham, MA, USA) was used to assess cell
metabolic activity over time (n = 4). At 3, 14, and 21 days after GFP-HUVECs seeding, cells
were incubated in 10% alamarBlue® in D-MEM without phenol red (Lonza, Levallois-Perret,
France) at 37 ◦C and 5% CO2. After 4 h, the supernatant was transferred to 96-well plates
and the absorbances at 570 and 595 nm were measured in a Multiskan FC plate reader
(Thermo Fisher Scientific, Illkirch-Graffenstaden, France) to determine the percentage of
reduced alamarBlue®.
2.7. Immunofluorescence and Immunohistochemistry
Bone substitutes seeded with cells were fixed with 4% PFA for 10 min at 4 ◦C and
rinsed with PBS, then demineralized and embedded in paraffin for 4 µm serial sections.
Rabbit anti-human PECAM1/CD31 (Microm, Brignais, France) and non-species-specific
anti-PECAM1/CD31 (Abcam, Paris, France), then secondary antibody raised against rabbit
antibodies and coupled with Alexa 594 fluorochrome (Molecular Probes, Life Technologies,
Thermo Fisher Scientific, Illkirch-Graffenstaden, France), diluted 1:200 in PBS 1% BSA,
were used. After multiple rinses in PBS, samples were incubated 10 min in 200 nM
4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, Saint-Quentin-Fallavier, France), for
nuclear counterstaining. Specimens were observed with a LEICA DM4000B epifluorescence
microscope (Leica Microsystems, Nanterre, France).
Mouse calvarial samples were fixed overnight at 4 ◦C in 4% paraformaldehyde and
embedded in paraffin. Sections (10µm) were used for immunohistochemistry (IHC) stain-
ing of osteopontin (Opn) in the osteoblasts. Slides were then blocked with 12% of Avidin
(in PBS) serum (Vector Laboratories, Burlingame, CA, USA) and incubated with mono-
clonal anti-mouse Opn primary antibody (dilution 1:200) (for IHC of Opn, Santa Cruz
Biotechnology, #SC 21742, Clinisciences, Nanterre, France) at 4 ◦C, followed by incubation
with biotinylated anti-rabbit/mouse IgG (Vector Laboratories, Eurobio Scientific, Les Ulis,
France) for 30 min at room temperature. The staining was visualized using the ImmPactTM
Dab Detection Kit (Vector, #SK4105, Vector Laboratories, Eurobio Scientific, Les Ulis, France)
by treating the sections for 30 min at room temperature. The slides were mounted using
Aqueous base mounting medium (ImmunoLogic, #VWRK4058, VWR, Strasbourg, France).
Biomedicines 2021, 9, 952 5 of 19
2.8. Bone Substitute Implants in Nude Mice
The experimental protocol fulfilled the authorization of the “Ministère
de l’Enseignement Supérieur et de la Recherche” under the agreement numbers
APAFIS#7740-2016112116448550 (20 September 2016) and APAFIS#26926-2020080410295545
(20 December 2020). The Ethics Committee of Strasbourg named “Comité Régional
d'Ethique en Matière d'Expérimentation Animale de Strasbourg (CREMEAS)” specifi-
cally approved this study. Nude male mice (Crl: NIH-Foxn1nu; Charles River, L’Arbresle,
France), 6 weeks old, were anesthetized with an intra-peritoneal injection of 100 mg kg−1
of ketamine (VIRBAC Santé Animale; Centravet, Nancy, France) mixed with 10 mg kg−1 of
Xylazine (Rompun® 2%, VIRBAC Santé Animale; Centravet, Nancy, France), and placed
on a heating plate kept at 37 ◦C. Five days before implant, each bone substitute was seeded
with 1.0× 105 hMSCs. For subcutaneous implant, a dorsal skin incision was performed and
the bone substitute (diameter = 5 mm) was placed between the skin and the muscle below.
Incisions were sutured with resorbable material and mice were kept under observation
for the whole experimentation time. After either 4 (n = 6) or 12 (n = 12) days post-implant
(dpi), implanted mice were sacrificed with an intra-peritoneal injection of a lethal dose of
ketamine. For implants in bone critical size defect, skin incision was performed, calvaria
(parietal zone of the skull) was drilled using a sterile round burr (500 µm deep and 5 mm
in diameter) and bone substitute (diameter = 5 mm) was placed in the defect. Incisions
were sutured with resorbable material and mice were kept under observation for the whole
experimentation time. Mice (n = 12) were sacrificed 12 dpi and explants were subject to
histological, TEM and/or micro-CT assessments.
2.9. Histological Staining
For HE staining, subcutaneous explants were fixed with 4% PFA, demineralized, and
embedded in paraffin for 7-µm serial sectioning. Samples were then subject to HE staining
and observed on a Leica DM4000B microscope (Leica Microsystems, Nanterre, France). For
quantitative analysis of the vascularization, ImageJ software was used. Number, mean size,
and total area of the blood vessels found in the explants were analyzed. At least 5 images
per section, 4 sections per sample were analyzed.
For Mallory staining, the explants were fixed with Bouin Hollande solution for 2 days.
Then, they were dehydrated through a series of increasing ethanol concentrations, cleared
with toluene, and embedded in paraffin wax. Sections were cut at 10 µm using a sledge
microtome and mounted on glass slides. After the removal of paraffin wax, the sections
were stained using Mallory staining for 2 days.
For Gomori staining, the explants were fixed with Bouin Hollande solution for 2 days
and embedded in paraffin wax. Sections were cut at 10 µm using a sledge microtome and
mounted on glass slides. After the removal of paraffin wax, the sections were stained using
Gomori trichrome.
2.10. Micro-Angiography and Quantitative Analysis of the Vasculature
Twelve days after subcutaneous implantation, mice were subject to deep general
anesthesia (sodium Pentobarbital 120 mg Kg−1). After opening the thoracic cage, an
infusion needle was placed in the left ventricle. Mice were in turn perfused (rate of
2 mL min−1) with heparin (50 U mL−1; to purge the cardiovascular system), then with 4%
PFA, PBS, and finally with radiopaque silicone rubber (Microfil® MV-122, Flow Tech Inc.
South Windsor, CT, USA). After perfusion, the heart was clamped to avoid leaks of the
contrast agent; mice were then placed at 4 ◦C, overnight to allow the polymerization of the
contrast agent. Explants were then post-fixed in 4% PFA for 48 h and then demineralized
with Ethylenediaminetetraacetic acid (EDTA, 15%, pH = 7.4) for 1 week at 37 ◦C under
constant slow agitation. The explants were mounted in 1% agar, in order to avoid any
movement of the sample during micro-CT acquisition. The tomography experiments
were carried out using the micro-CT X-ray system nanotom® M (GE Sensing & Inspection
Technologies GmbH, Wunstorf, Germany) equipped with a 180 kV–15 W high-power
Biomedicines 2021, 9, 952 6 of 19
nanofocus tube with a tungsten transmission target. The X-ray micro-CT was performed
with an isotropic pixel size of 5 µm2 and a field of view of about 15.4 × 12.0 mm2. For
each measurement, the sample was irradiated by X-rays of 60 kV acceleration voltage
and 310 mA beam current. At each rotation angle position, six images were acquired and
averaged to a projection. Moreover, 1700 projections over 360◦ resulted in a total scan
duration of about 100 min.
The data acquisition and reconstruction were performed with the phoenix datos|x 2.0
software (phoenix|x-ray, GE Sensing & Inspection Technologies GmbH, Wunstorf,
Germany).
Grey level images obtained from micro-CT scan were segmented into two classes
to distinguish the voxels within the vessels from those on the outside. For each image,
manually tuned threshold was applied to intensity levels. A structuring element 10 µm
wide was applied to each image in order to de-noise the segmentation. Then, the connected
sets of voxels smaller than 20 µm3 were erased. After segmentation, the resulting vessels
were sketched as skeletons, where a skeleton is defined as the ordered set of the points that
defines both the center line and the local radius of a vessel-like shape, as for the algorithm
previously described [64].
2.11. Transmission Electron Microscopy (TEM)
Explants at 12 dpi or 4 wpi (weeks post-implant) were fixed in 2.5% glutaraldehyde
and 2.5% PFA in 0.1 M cacodylate buffer, pH 7.4 after decalcification. The samples were
post-fixed in 1% osmium tetroxide, dehydrated, conditioned in propylene oxide, and em-
bedded in Epon 812, Spurr epoxy resin (Electron Microscopy Sciences, Ft. Washington, PA).
Semithin sections (2 µm) were stained with 1% Toluidine blue in 1% sodium borate, exam-
ined by Leica optical microscope (LEICA DMLB, Leica Microsystems GmbH; Germany).
Ultrathin sections (70 nm) were prepared on a Leica Ultracut UCT ultra microtome (Leica
Microsystems), contrasted with uranyl acetate (Laurylab, Brindas, France) and lead citrate
(Euromedex EMS, Souffelweyersheim, France) and examined at 70 kV with a Morgagni
268D electron microscope (FEI-Phillips, Thermo Fisher Scientific, Illkirch-Graffenstaden,
France). Digital images were captured using a Mega View III camera (Soft Imaging System,
Münster, Germany).
2.12. Statistical Analysis
Statistical analysis was carried out with BioStatGV (Sentiweb, France) and Prism5
(GraphPad, La Jolla, CA, USA). The alamarBlue metabolic assay, histological data, and
microangiography data were analyzed with unpaired, two-tailed Student’s t-test. When
variance was found different between sets of data, then the Welch correction was applied.
3. Results
3.1. Design and Modeling of the Pro-Angiogenic Smart Nano-Active Complexes
In order to improve the vascularization of a graft implanted in a critical-sized bone
defect, we nano-functionalized an FDA-approved biphasic bone substitute with pro-
angiogenic nano-active complexes (patent pending) (Figure 1A,B) [38–41]. Heparin is
critical for the angiogenic activity of VEGF, increasing both the kinase activation of VEGF
receptor 1 and the mitogenic activity of VEGF [34,35,53,65]. Therefore, we first investigated
the suitability of using the HEP/VEGF165 complex to functionalize the bone substitute.
Heparin, VEGF165, or a complex thereof was deposited dropwise on a glass coverslip, and
visualized by scanning electron microscopy (Figure 1B and Supplementary Figure S1A–C).
Complexed HEP/VEGF165 formed large agglomerates (60.0 ± 15.4 nm), as confirmed by
AFM imaging (Supplementary Figure S1D).
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Figure 1. Third-generation hybrid bone substitute nano-functionalized with pro-angiogenic
molecules. (A) Current strategies for bone repair. (B) The combination of pro-angiogenic smart
nano-active complexes (SNCs), human mesenchymal stem cells, and biphasic bone substitute used
in this study. (C) Molecular modeling of the HEP/VEGF complex, where VEGF is displayed as
homology model (green), and HEP as stick model (blue). Sulfur moieties are shown in yellow.
To understand why complexed HEP/VEGF aggregates had such a large size, we
modeled the molecular interaction between HEP and VEGF165 using molecular dynamics
simulations (Figure 1C). Heparin is a linear sulfated polysaccharide, with high negative
charge, while the surface electrostatic potential of the HEP-binding domain of VEGF165
is positively charged [66]. Docking simulations of the HEP model to the NMR model
of VEGF165 were therefore performed using the sulfate anions of HEP and the arginine
(Arg) residues of VEGF165 as a guide to model the molecular interactions. Most of the
positive Arg residues are either clustered in the central domain of VEGF165 (Arg35, Arg39,
Arg46, Arg49) or within a loop in its N-terminus (Arg13, Arg14). These regions, according
to the calculated electrostatic potential of the solvent accessible surface, represent the
binding site for a high negatively charged molecule, such as HEP. The HEP/VEGF165
complex models generated using molecular docking were subjected to steepest decent
energy minimization, followed by equilibration and a 30 ns molecular dynamics production
run. The complex models were then ranked according to their energy, by means of the
Molecular Mechanics Poisson–Boltzmann Surface Area (MM/PBSA) method [67]. The
resulting HEP/VEGF165 complex structure with the lowest energy (Figure 1C) clearly
indicates that the net charge plays a significant role in the affinity of HEP (stick model in
Figure 1C) to VEGF165 (homology model in Figure 1C). These results can be explained by
the fact that the sulfate groups of HEP (yellow in Figure 1C) strongly interact with the
side chains of the Arg residues and the leucine 17 and threonine 47 residues of VEGF165,
stabilizing the HEP/VEGF165 complex and allowing the formation of large agglomerates.
3.2. Bone Substitutes Equipped with HEP/VEGF-SNCs Improve In Vitro Organization of
Endothelial Cells
The pro-angiogenic HEP/VEGF165 complexes (HEP/VEGF, in short) were integrated
into chitosan SNCs and deposited on the bone substitute by using the nano-reservoir
technology. The nano-active bone substitutes were observed at the SEM and compared
to non-functionalized, chitosan-only SNCs (NF-SNCs). After six cycles of deposition, we
observed a homogeneous distribution of either HEP/VEGF- or NF-SNCs, on both the
mineral (Figure 2A,C) and the collagen (Figure 2B,D) portions of the bone substitute. To
investigate the pro-angiogenic effects of the nano-functionalized bone substitute, either
HEP/VEGF-SNCs, HEP/bovine serum albumin (BSA)-SNCs or NF-SNCs were deposited
on fragments of bone substitutes that were in turn seeded with hMSCs (at t0) and Green
fluorescent protein-expressing human umbilical vein endothelial cells (GFP-HUVECs, at
day 7). The organization of the endothelial cells was monitored after 21 days of culture.
In the presence of HEP/VEGF-SNCs, GFP-HUVECs organized themselves in vessel-like
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structures with visible lumen (red asterisks in Figure 2E). On the contrary, in the presence
of either NF-SNCs or HEP/BSA-SNCs (Figure 2E), the endothelial cells remained mostly
distributed as single cells on the graft. The pro-angiogenic activity of the SNCs was
assessed by counting the number of GFP-HUVECs organized in vessel-like structures. On
functionalized therapeutic bone substitute, these were on average 3.4± 0.5 cells long, while
on bone substitute control or on functionalized with HEP/BSA, these were 1.2 ± 0.1 and
1.4 ± 0.2 cells long, respectively (p ≤ 0.001) (Figure 2F). Since the presence of HEP/BSA-
SNCs produced results similar to those found for NF-SNCs, we concluded that the capacity
of the nano-active bone substitute to promote the organization of endothelial cells in vitro
depended on the presence and the cellular availability of the HEP/VEGF complex. We also
assessed the metabolic activity of the cells seeded on non-functionalized bone substitute
and compared it with that of cells seeded in the presence of HEP/VEGF-SNCs, by means of
alamarBlue assay. In both conditions, the reduction of the alamarBlue increased from day
0 to day 21 (Figure 2G), suggesting that the nano-functionalized bone substitute was not
cytotoxic. No significant differences were observed between NF- and HEP/VEGF-SNCs
along the culture period considered. However, while the cells cultured with NF-SNCs
showed an abrupt metabolic increase between day 3 and day 14 (p ≤ 0.1), the cells cultured
in the presence of HEP/VEGF-SNCs showed a steady metabolic increment (p ≤ 0.05 and
p ≤ 0.01, for day 3–14 and day 14–21, respectively). Since metabolic increases are generally
associated with cell proliferation and growth, our data suggest that HUVECs proliferate less
in the presence of strong differentiation cues, like those provided by the HEP/VEGF-SNCs.
3.3. In Vivo Vasculoneogenesis Induced after Subcutaneous Implantation of Nano-Active
Bone Substitute
Bone substitutes functionalized with HEP/VEGF-SNCs improved the organization
of endothelial cells in vitro, eliciting the formation of vessel-like structures. Therefore, we
assessed if and how the angiogenic nano-active bone substitute could effectively trigger
vasculoneogenesis in vivo. We subcutaneously implanted either HEP/VEGF-SNCs or
NF-SNCs bone substitutes in the dorsal of nude mice. Prior to implant, the bone substitutes
were seeded with hMSCs and cultured for 7 days. Bone substitutes were explanted from
mice after 4 or 12 dpi, and their degree of vascularization was evaluated at the histological
levels (Figure 3A,B). In general, explanted nano-active bone substitutes showed a better
recruitment of host blood vessels compared to NF ones (yellow arrowheads in Figure 3A,B).
Neither inflammatory infiltration, foreign body granulomas, scarring incidents, nor signs
of rejection were observed at the implantation site. The quantification of the blood vessels
found in the core of the bone substitutes showed a significant increase only in the presence
of HEP/VEGF-SNCs (14.8 ± 1.7 mm−1 and 51.0 ± 12.9 mm−1 at 4 and 21 dpi, respectively;
p = 0.002), compared to NF bone substitutes (13.2 ± 2.74 mm−1 and 22.6 ± 8.0 mm−1 at
4 and 12 dpi, respectively) (Figure 3C, left panel). No significant differences were observed
at 4 dpi in the diameter of the blood vessels recruited (17 ± 1 µm vs. 18 ± 2 µm, in
HEP/VEGF-SNCs and NF-SNCs bone substitutes, respectively) (Figure 3C, central panel)
and in the relative vessel area (below 1% in either condition) (Figure 3C, right panel). The
picture changed quite dramatically at 12 dpi, when both the size and the relative area of the
host blood vessels found in the HEP/VEGF-SNCs bone substitutes increased 1.5- (p = 0.002)
and 8-fold (p = 0.0003), respectively, while no differences were observed in the NF-SNCs
bone substitutes (Figure 3C). These results show that the presence of HEP/VEGF SNCs
increased the number and the size of the blood vessels recruited from the host tissues in
the core of the bone substitute, a condition necessary to support the functional engraftment
of the implant and to unleash its therapeutic potential.
3.4. Human MSCs Seeded on the Bone Substitute Actively Contributed to Vasculoneogenesis
The vessels observed within the bone substitutes subcutaneously implanted in nude
mice look well connected to the surrounding vessels because none of the implanted animals
suffered from bleeding. In order to have a closer look at the morphology of the newly-
formed vessels, we analyzed them at the ultrastructural level. The vessels found within
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the bone substitutes were characterized by the presence of tightly connected endothelial
cells of normal morphology, surrounded by mural cells that provide structural stability
to the vessel (Figure 3D,E). The functionality of the blood vessels that are found within
the bone substitute after implant, together with the speed at which they formed, are both
of crucial importance to avoid the necrosis of the cellular component of the graft. Both
functionalized and non-functionalized bone substitutes were seeded with hMSCs before
implant. Mesenchymal stem cells are multipotent stem cells known to differentiate in many
cell types, like osteoblasts, adipocytes, chondrocytes and even neurons [68]. Several studies
also showed that MSCs could efficiently differentiate in endothelial cells in vitro [50,51].
Therefore, we investigated whether the hMSCs seeded on the bone substitute contributed
to the formation of the blood vessels found within the grafts subcutaneously implanted.
By means of immunohistochemistry, we detected several human platelet and endothelial
cell adhesion molecule 1 (PECAM1)-positive endothelial cells (Figure 3F, top panels) which
took part to the formation of the new blood vessels in the bone substitute (white asterisks
in Figure 3F). As shown in the immunohistochemistry using an antibody that cross-reacted
with both human and mouse PECAM1, these cells were a substantial portion of the
endothelial cells found within the graft (Figure 3F, mid panels), suggesting a non-trivial
contribution by the transplanted hMSCs. As expected, no signal was detected using
the anti-human-PECAM1 antibody on a control mouse bone (Figure 3F, lower panels).
These results indicate that the formation of new blood vessels within the implanted bone
substitutes resulted from the simultaneous presence of both the pro-angiogenic SNCs and
the hMSCs. We therefore concluded that the release of angiogenic growth factors and the
differentiation of the transplanted hMSCs in endothelial cells synergistically contributed to
the vasculoneogenesis observed within the nano-functionalized bone substitutes.
Figure 2. Nano-functionalization of the bone substitute with HEP/VEGF-SNCs and its effect on
the organization of umbilical cord-derived endothelial cells in vitro. (A–D) SEM pictures of bone
substitutes deposited with either - (NF-) (A,B) or HEP/VEGF- (C,D) SNCs. The SNCs were found on
both the mineral (A,C) and the protein (B,D) constituents of the biphasic bone substitute. Scale bar in
(A,C): 5 µm; in (B,D): 10 µm. (E) Fluorescence micrographs of GFP-HUVECs co-seeded with hMSCs
on the bone substitute deposited with either NF-, HEP/BSA-, or HEP/VEGF-SNCs, after 21 days of
culture. Nuclei counterstained with DAPI. Scale bars: 150 µm. (F) Number of GFP-HUVECs found
organized in vessel-like structures (red asterisk in (E)) on NF-, HEP/BSA-, or HEP/VEGF-SNCs bone
substitutes. Bars represent mean ± SEM (n = 20 per condition); ***: p < 0.001. (G) The presence of
reduced alamarBlue® (indicating increased cell proliferation/cell metabolism) was quantified for
the cells seeded on bone substitutes either deposited with NF- or HEP/VEGF-SNCs, after 3, 14, and
21 days of culture. Values expressed as mean ± SEM (n = 4). *: p < 0.1; ***: p < 0.01.
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Figure 3. Vasculoneogenesis in bone substitutes subcutaneously implanted in nude mice. (A,B) H&E staining of bone
substitutes (green lines) with either empty (NF-) (A) or HEP/VEGF- (B) SNCs, at 12 dpi. Yellow arrowheads indicate
blood vessels. Scale bars: 200 µm. The images at the top right show enlargements of blood vessels. Scale bars: 20 µm. (C)
Quantitative analysis of the vessels found in the implanted bone substitutes. The average number and diameter of the
vessels found, together with the average surface covered are given at 4 and 12 dpi. Values are expressed as mean ± SD of
at least five images/section and four sections/sample. **: p ≤ 0.05. (D,E) Ultrastructural view of a blood vessel found in
the HEP/VEGF-SNCs bone substitute, shown as a transverse section. Mural cells enveloping the blood vessels (e.g., the
pericyte indicated with a red asterisk) were found in the nano-active bone substitute. (E) This is the enlargement of the
area delimited by the yellow frame in (D). No blood cells are in the lumen of the vessel, as a contrast agent was perfused
(residues indicated with a blue asterisk). E: endothelial cell; eN: nucleus of the endothelial cell; P: pericyte; pN: nucleus of
the pericyte. Scale bars: 5 µm in d, 2 µm in e. (F) Endothelial cells of human origin in the bone substitute, as revealed with
anti-human (top panels) or anti-human/mouse PECAM1 antibody (mid panel). Mouse control bone was negative to the
anti-human PECAM1 antibody (lower panel). Scale bars: 200 µm.
3.5. Pro-Angiogenic Bone Substitutes Promoted the Formation of New Bone in a Critical-Sized
Calvarial Bone Defect
To investigate if the nano-functionalized bone substitutes could improve the speed
of new bone formation, a portion of the skull roof 5 mm large and 0.5 mm deep was
drilled out in nude mice (induced critical-sized calvarial bone defect), and filled with
either HEP/VEGF-SNCs or the NF-SNCs bone substitutes (see Supplementary Figure S2).
Moreover, four wpi, mice were sacrificed and macroscopic observation of NF-SNC bone
substitutes revealed a clear boundary between the implant and the healthy bone and a
patchy appearance of the implant, which reflected the hybrid composition of the bone
substitute (n = 5; Figure 4A). In contrast, the boundaries between the HEP/VEGF-SNC
bone substitutes and the healthy bone were not evident and the appearance of the implant
looked indistinguishable from the healthy bone, suggesting a very good integration of the
newly-formed bone with the surrounding bone (n = 5; Figure 4A). Histological analysis
with either Gomori or Mallory staining confirmed the better integration of the HEP/VEGF-
SNC bone substitutes, suggesting the formation of abundant new bone, which engulfed
the mineral portions of the bone substitute. On the contrary, the new bone formation in
NF-SNC bone substitutes looked patchy, with large areas of intact mineral bone substitute
in between (Figure 4B). Immunohistochemistry against Osteopontin confirmed the abun-
dance of newly-formed bone in HEP/VEGF-SNC bone substitute (Figure 4C). Toluidine
blue staining of semi-thin sections confirmed the continuous presence of both capillaries
and osteocytes within the HEP/VEGF-SNC bone substitutes, where capillaries within the
NF-SNC bone substitutes were only found between the mineral portions of the implanted
Biomedicines 2021, 9, 952 11 of 19
bone substitute (Figure 4D). Transmission electron microscopy analysis of ultrathin sections
showed the presence of osteoblasts and osteocytes within the HEP/VEGF-SNC bone sub-
stitute, but not within the NF bone substitute (Figure 4D). Together, these data showed that
the abundant vascularization induced by the HEP/VEGF-SNC bone substitute accelerated
the formation of new bone after the critical-sized defect induced in the mouse calvarial
bone, compared to the NF bone substitute.
Figure 4. Bone regeneration in critical-sized calvarial bone defects implanted with bone substitutes.
(A) Macroscopic evaluation of the calvarial bones at 4 wpi implanted with either NF- or HEP/VEGF-
SNCs. Scale bar: 5 mm. (B) Gomori and Mallory stains of sections of the calvarial bones implanted
with either NF- or HEP/VEGF-SNCs. In Gomori trichrome stain, collagen is light blue, erythrocytes
are pink, osteoblasts/osteocytes are violet/brown; in Mallory trichrome stain, cartilage is blue, bone
components are orange to red and nuclei are brown. HB: Healthy bone; white asterisk: newly-formed
bone within the implanted bone substitute. Scale bar: 50 µm. (C) Sections of the specimens shown
in (B) underwent immunohistochemistry analyses against Osteopontin. HB: healthy bone. Scale
bar: 50 µm. (D) Toluidine blue staining on semi-thin sections (upper panels) and transmission
electron micrographs on ultrathin sections (mid and lower panels). Red arrowhead: capillary; white
arrowhead: osteocyte; cyan arrowhead: osteoblast; yellow arrowhead: granulocyte; black arrowhead:
megakaryocyte; green arrowhead: erythroblast; red asterisk: capillary lumen with blood cells; cyan
asterisk: mineral part of the biphasic bone substitute; yellow asterisk: bone matrix. Scale bar: 25 µm
(upper panels); 10 µm (mid panels), 5 µm (lower panels).
3.6. Nano-Active Bone Substitutes Promoted Vasculoneogenesis in a Critical-Sized Calvarial
Bone Defect
We then tested the pro-angiogenic effects of the nano-active HEP/VEGF bone sub-
stitutes in the critical-sized bone defect mouse model. At 12 dpi, implanted animals
were perfused with a radiodense rubber contrast agent and the bone substitutes were
in turn explanted and subject to micro-CT scan. Relevantly, we could not detect any
leakage of the contrast agent in the surrounding bone of none of the implanted mice
(Supplementary Figure S3), suggesting that the newly-formed vessels were both functional
and perfectly integrated in the host vascular system. The 3D micro-angiographies of the
transplanted mice (3D rendering of micro-CT scan images; Supplementary movie) were
prepared in order to show the influence elicited by the presence of the HEP/VEGF-SNCs on
the activation of vasculoneogenesis within the graft (Supplementary Figure S4, black arrow-
heads). Differently to what we observed with the empty SNCs (Figure 5A,B, left panels),
the newly-formed vessels penetrated intimately the HEP/VEGF-SNCs deposited bone
substitutes, virtually spanning the entire volume of the implant (Figure 5A,B, right panels).
Remarkably, when we used Standard Euler distances to generate distance maps to the clos-
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est neighboring vessel from the segmented micro-CT images acquired, we saw that both the
trend of the curves and the mode of the distributions (0.32, 0.25, and 0.05 mm for 1NF, 2NF,
and 3NF, respectively; 0.06, 0.02 and 0.05 mm for 1F, 2F and 3F, respectively) (Figure 5C)
clearly indicated that the average distance of any point to the nearest neighboring vessel
is smaller in the nano-active bone substitutes compared to the NF ones (p = 0.0423). The
analyses also revealed that the vascular density in NF bone substitutes was 0.75 ± 0.99%,
where in HEP/VEGF-SNCs bone substitutes was 2.8 ± 0.76% (p = 0.0167), which is almost
four times higher.
Figure 5. Quantitative analysis of the vasculature found in the bone substitutes implanted in critical-
sized calvarial bone defects. (A) Micro-CT scans of four representative bone substitutes, deposited
with empty (1NF, 2NF) or pro-angiogenic HEP/VEGF (2F, 5F) smart nano-active complexes (SNCs),
12 days after implant. Vessels within the bone substitutes are shown in red. Scale bars: 1 mm. (B)
Skeletons of the segmented CT images of the vascular networks found in 4 representative bone
substitutes, either deposited with NF-SNCs (1NF, 2NF) or with HEP/VEGF-SNCs (2F, 5F). Lighter
colors display vessels of larger size. Scale bars: 1 mm. (C) Relative density of the vascular networks
in 6 bone substitutes, either deposited with NF-SNCs (light grey dots) or with HEP/VEGF-SNCs
(dark grey dots), represented in function of the average distance to the closest neighbor vessel. The
red and blue dotted lines represent the mean values for HEP/VEGF-SNC and NF-SNC deposited
bone substitutes, respectively. *: p < 0.1; **: p < 0.05. (D) Hybrid bar/dot plot charts of the relative
number of vessels in NF-SNC or HEP/VEGF-SNC deposited bone substitutes, as a function of the
blood vessel diameter, 12 days after implant. *: p < 0.1; ***: p < 0.01. Bars represent Mean ± SD
(n = 3).
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Additionally, the diameter of the blood vessels found in the implanted grafts was
measured. In general, bone substitutes deposited with HEP/VEGF-SNCs were colonized
by vessels of a larger size (Figure 5D). While the large majority of the vessels found in
non-nano-functionalized bone substitutes had a diameter smaller than 0.01 mm (93.55%
vs. 84.49% in HEP/VEGF- and NF-SNCs bone substitutes, respectively; p = 0.091), blood
vessels with a diameter between 0.02 and 0.03 mm were almost three times more frequent
in HEP/VEGF-SNCs bone substitutes compared to NF-SNCs ones (1.91% vs. 0.68% in
HEP/VEGF- and NF-SNCs bone substitutes, respectively; p = 0.0011). Moreover, vessels
larger than 0.05 mm could only be found in HEP/VEGF-SNCs bone substitutes (Figure 5D).
In summary, these data indicate that the presence of the HEP/VEGF-SNCs entrapped
into nano complexes combining heparin and chitosan as a coating of bone substitute
mineral blocks promoted the formation of a denser cloud of vessels with larger diameters
within the treated bone defect, an essential precondition for the successful filling of the
defective bone.
4. Discussion
The speed at which the host vasculature colonizes implanted 3D biomaterials is ap-
proximately 10 µm per day [16–18,20]. Consequently, grafts implanted in critical-sized
bone defects take several weeks for the proper vascularization, leading to necrosis, es-
pecially at the core of the implant, and to a failure to properly engraft [43]. In order to
promote vasculoneogenesis inside bone substitutes, angiogenic growth factors, such as
VEGF, incorporated into the scaffold material were reported to be promptly released upon
the degradation of the scaffold [31,37,69,70]. In the case of bone substitutes, however,
rapid degradation of the implant is not advisable, as the scaffold material has to fill the
bone defect and compensate for the loss of its mechanical properties. On the other hand,
a passive release of angiogenic factors, such as that found in the Augment® Bone Graft
system (Wright Focus Excellence, USA), soaked in 0.3 mg/mL recombinant human platelet-
derived growth factor B (rhPDGF-BB), also leads to problems related to both the initial
high concentration and then quick depletion of the growth factor [36,43]. Therefore, an
accessible, localized, and sustained physiological concentration of VEGF is required for
mature blood vessels to successfully develop within the bone defect.
The strategy presented in this work is based on the nano-functionalization of bone
substitute material, which allows the release of therapeutic angiogenic molecules. In
our approach, VEGF165 was complexed with HEP in order to maximize its angiogenic
effects. The evidence we collected revealed that the HEP/VEGF165 complex formed larger
aggregates than either VEGF165 or HEP alone (Supplementary Figure S1A–D), as a result
of the chemical–physical interaction with HEP, as anticipated with our computer modeling
(Figure 1C). The functionalization of bone substitutes using smart nano-active complexes
(SNCs) is effective in overcoming the side effects associated with a high local dose of
VEGF. Moreover, free VEGF165 has a very short half-life when exposed to the extracellular
environment (approximately 90 min), yet does not degrade within the chitosan SNCs, and
is therefore available to the cells for a prolonged time, as we and others have shown in
previous studies [22,29,41]. In this work, we showed how the HEP/VEGF-SNCs induced
the organization of endothelial cells in vessel-like structures in vitro (Figure 2E,F). This was
also proved in vivo. Either implanted subcutaneously (Figure 3A–C) or in critical-sized
calvarial bone defects (Figure 5A–D), the pro-angiogenic smart bone substitutes were able
to promote vasculoneogenesis. Although the spatial distribution of the host blood vessels
in one of the NF-SNC bone substitutes implanted in the calvarial defect was found to be
similar to that of the HEP/VEGF-SNC bone substitutes, its vascular density was lower
(1.9%) compared to the average found in the nano-active bone substitutes (2.8%). The most
striking difference between NF- and HEP/VEGF-bone substitutes was, however, in the
size of the newly-formed blood vessels. This could be explained as a difference in the
maturity of the vessels, as observed in the histological specimens. Most importantly, the
higher density and the bigger diameter of the newly-formed vascular network observed
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in HEP/VEGF-SNCs bone substitutes, promoted a better regeneration of the bone within
critical-sized defects in mouse calvarial bone (Figure 4A–D). Following the implant of
mineral-based bone substitutes, one major drawback is the long persistency of the mineral
blocks, which prevents the growth of new vasculature within the bone substitute and
slows down the replacement by newly-formed bone. In our HEP/VEGF hybrid bone
substitutes, the new blood vessels meet fewer mineral blocks that are in their way and
are thus able better to support the formation of new bones (Figures 5 and 6; NF: non-
functionalized HEP/VEGF-SNCs, F: functionalized HEP/VEGF-SNCs). Most importantly,
we have observed the newly-formed vessels penetrated intimately the HEP/VEGF-SNCs
deposited bone substitutes, virtually spanning the entire volume of the implant, which
is totally different from what we observed with the empty SNCs (Figure 5A,B). After the
microCT quantitative and qualitative analyses for the new blood vessels formed with or
without SNCs, we elucidated the mechanism to understand how the new-formed vessels
can no longer encounter mineral blocks and pursue their course of vasculature (Figure 6).
Figure 6. Mechanistic illustration of vascularized new generation of hybrid bone substitute.
With the emergence of third-generation biomaterials, approaches using MSCs as
therapeutic agents have garnered much interest for clinical applications [44,45]. These
cells are not only able to differentiate into mature tissues, but could also modulate the
immune response, prevent apoptosis, and promote angiogenesis via the secretion of trophic-
factors [71]. Moreover, MSCs have been shown to stabilize newly-formed blood vessels
by differentiating into both endothelial and mural cells [49,51]. The combined use of
hMSCs, endothelial cells, and 3D biomaterials was shown to increase the formation of
both vascular networks and new bone tissue [41,42,71]. Based on this knowledge, we
opted to combine the pro-angiogenic bone substitute with MSCs, assessing how these
two elements could synergistically promote vasculoneogenesis in vivo. As shown here,
besides the recruitment of endothelial cells from the host, the hMSCs pre-seeded on the
nano-functionalized bone substitute actively contributed to the formation of new blood
vessels, which is demonstrated by the several endothelial cells of human origin found in
the vasculature within the bone substitute (Figure 3F).
In summary, our results clearly indicate that the presence of the HEP/VEGF-SNCs
entrapped into nano complexes as a coating of bone substitute mineral blocks promoted
the vascularization stopped before by the mineral component. We demonstrated that our
therapeutic bone substitute could indeed offer an effective substitution for either auto- or
allografts in the treatment of large bone defects. Concomitantly, our innovative strategy
allows modifications in the composition of the active elements (both cells and growth
factors) so that it could be used for other tissues application.
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5. Conclusions
Presently, autologous bone grafting (auto-transplant) is the gold standard in the
treatment of large bone defects. With ≥2 million procedures per year worldwide, it is the
second most common tissue transplantation after blood transfusion [11]. However, it has
downsides. Bone autografts present more complications than the use of synthetic bone
substitutes in terms of infections; moreover, they have a higher cost [72,73]. Allogenic bone
grafts are even more expensive than autografts, as they have to be properly treated prior to
the clinical use [74,75]. However, autografts necessarily introduce a second operative site,
a longer operating room time, and a worse and longer-lasting post-operative chronic pain,
which increase both the distress of the patient and the overall costs of the technique [64].
Therefore, advanced therapeutics materials are needed to overcome the current limitations
(i.e., the lack of blood vessels recruitment from host tissues and the necrosis induced
at the core of the implanted bone substitute) and to induce the vascularization of the
implanted bone substitutes, which in turn favors the regeneration of functional bone tissue.
In this study, we developed a therapeutic bone substitute based on the combined presence
of proangiogenic, smart nano-active complexes that aim to improve vasculoneogenesis
in critical-sized bone defect. The results presented in this work have great relevance
from both biomedical and public health perspectives. They showed that our innovative
strategy, applied to a bone substitute already used in the clinic, was able to (i) induce
the functional organization of endothelial cells in vessel-like structures in vitro, and (ii)
promote vasculoneogenesis in bone substitutes implanted either subcutaneously or in
critical-sized calvarial bone defects.
To conclude, we reported here the quantitative analysis of the functional vasculature
formed in the hybrid bone substitutes implanted in critical-sized bone defects. We have
also elucidated the mechanism to understand how the newly-formed vessels can no longer
encounter mineral blocks and pursue their course of vasculature, giving to our advanced
therapeutic bone filling’s great potential to be used in many applications, combining filling
and regenerative medicine that currently fall short because of problems related to the lack
of oxygen and nutrients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biomedicines9080952/s1. Figure S1. Third-generation hybrid bone substitute nano-
functionalized with pro-angiogenic molecules. (A–C) SEM pictures of VEGF (A), HEP (B) and
HEP/VEGF SNCs (C) after deposition on glass slides. Scale bar: 500 nm. (D) The HEP/VEGF com-
plex shown in (c), representative of the HEP/VEGF nanocomplexes screened (n = 6), was acquired
with an atomic force microscope (AFM). False colors indicate depth, as for the side bar. Measure-
ments taken along the dashed line are plotted in the chart to the right. Figure S2. Iso-surface 3D
reconstruction view of the filled defect before demineralization. Red arrows show hybrid bone
substitute (polymeric and mineral blocks), blue arrows show host bone and violet big arrows show
mineral blocks. Figure S3. Iso-surface 3D reconstruction view of the functionalized hybrid bone
substitute after demineralization. Ellipsoid region of interest (ROI) corresponding to bone substitute
volume and its neovascularization (in red) showing that no bleeding occurred. Figure S4. Iso-surface
3D reconstruction view of the functionalized hybrid bone substitute after demineralization. Whole
view of cranial and bone substitute vascular network (yellow). Black arrowheads indicate the host
blood vessels entering the bone substitute. Supplementary movie: Bone substitute implanted in a
critical-sized calvarial bone defect at 12 dpi. The animation shows the bone substitute within the
calvarial defect and the surrounding tissues, before (0–25 s) and after (26–66 s) demineralization. The
host blood vessels become visible within the bone defects after demineralization.
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